Source: Independent Seed Professional Association (IPSA)
For years, the IPSA Seed Treatment Trials have delivered trusted, independent insights to help members evaluate product performance.
In 2026, the program takes a bold step forward — and the biggest benefit may be for Independent Seed Companies.
For the first time, IPSA members will have the opportunity to submit their own hybrids and varieties into the trials, paired with any seed treatment combinations they want to evaluate. This means you can see your products in action against industry checks, across multiple locations, under independent third party evaluation.
Even better: the data is yours to keep. Results remain confidential, giving you a private, unbiased look at how your genetics and treatments stack up against alternatives in the marketplace.
This new option transforms the IPSA Trials into more than just an industry benchmark — it’s a tool for your own product development, marketing, and strategic decision making.
Stay tuned: in upcoming articles, we’ll highlight other new features of the 2026 program, including larger strip trials, advanced data layers, and improved reporting.
